Johanna Friedl-Naderer - Sep 3, 2024 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role: Chief Commercial Officer
Signature: /s/ Richard Scalzo, Attorney-in-Fact
Stock symbol: DYN
Transactions as of: Sep 3, 2024
Transactions value $: $0
Form type: 4
Date filed: 9/3/2024, 06:16 PM
Previous filing: Mar 7, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DYN	Common Stock	Award	$0	+58.4K		$0.00	58.4K	Sep 3, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DYN	Stock Option (Right to Buy)	Award	$0	+185K		$0.00	185K	Sep 3, 2024	Common Stock	185K	$31.94	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of shares of Common Stock issuable under 58,400 restricted stock units ("RSU"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on September 3, 2025.
F2	This option was granted on September 3, 2024. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on September 3, 2025, and the remainder vesting in equal quarterly installments thereafter, subject to continuous service.